Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 15 Aug 2018 According to a Neurocrine Biosciences media release, data will be presented at the 2018 World Congress on Parkinson's Disease and Related Disorders(IAPRD) .
- 03 Aug 2017 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
- 09 May 2017 According to a Neurocrine Biosciences media release, the Company announced that in July 2017 it plans to complete this roll-over study.